| scholarly article | Q13442814 |
| P50 | author | Florian Herse | Q47804678 |
| Gerd Wallukat | Q63288594 | ||
| Ralf Dechend | Q63812628 | ||
| Babbette LaMarca | Q88459247 | ||
| P2093 | author name string | James N Martin | |
| Kedra Wallace | |||
| Abram Weimer | |||
| P2860 | cites work | What we have learned about preeclampsia | Q28196892 |
| Preeclampsia: linking placental ischemia with cardiovascular-renal dysfunction. | Q34446743 | ||
| Recent Insights into the pathogenesis of pre-eclampsia | Q34682287 | ||
| Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. | Q34702420 | ||
| Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Activating auto-antibodies against the AT1 receptor in preeclampsia | Q36010629 | ||
| Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling | Q36050771 | ||
| Role of the renin-angiotensin system in the pathogenesis of preeclampsia | Q36064478 | ||
| B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? | Q36106119 | ||
| Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. | Q36123039 | ||
| Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia | Q36380482 | ||
| The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy | Q36407259 | ||
| Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature | Q36914728 | ||
| Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia | Q37079628 | ||
| Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia | Q37119326 | ||
| AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia | Q37132801 | ||
| Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. | Q37193763 | ||
| Are we getting closer to a Nobel prize for unraveling preeclampsia? | Q37307973 | ||
| Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia | Q37421465 | ||
| Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats | Q37436219 | ||
| Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. | Q37447371 | ||
| Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade | Q37459545 | ||
| Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production | Q40395261 | ||
| Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro: morphological and biochemical evidence | Q41098649 | ||
| Preeclampsia: an endothelial cell disorder | Q41281924 | ||
| Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. | Q41934808 | ||
| Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. | Q43576536 | ||
| Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction | Q43744794 | ||
| Effect of angiotensin II synthesis blockade on the hypertensive response to chronic reductions in uterine perfusion pressure in pregnant rats. | Q43744800 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Role of reactive oxygen species in endothelin-induced hypertension | Q44521159 | ||
| Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 | ||
| Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia | Q46332630 | ||
| Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion | Q46877931 | ||
| Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies | Q46878600 | ||
| Inflammatory cytokines, vascular function, and hypertension | Q47606320 | ||
| Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. | Q51037509 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. | Q51139503 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. | Q51359651 | ||
| Immunology in hypertension, preeclampsia, and target-organ damage. | Q52909791 | ||
| IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. | Q53491305 | ||
| Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. | Q54661322 | ||
| Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe pre-eclampsia | Q67956897 | ||
| Endothelial cell activation by tumour necrosis factor-alpha (TNF-α and the development of pre-eclampsia | Q71649480 | ||
| Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension | Q73733035 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Pathophysiology of pregnancy-induced hypertension | Q74039094 | ||
| Severe persistent pemphigoid gestationis: long-term remission with rituximab | Q80439219 | ||
| Pre-eclampsia | Q81446389 | ||
| An emerging role for inflammatory cytokines in hypertension | Q82508329 | ||
| Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia | Q82705098 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | B-cell | Q188930 |
| hypertension | Q95566669 | ||
| P304 | page(s) | 865-871 | |
| P577 | publication date | 2011-02-28 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes | |
| P478 | volume | 57 |
| Q27003069 | A leading role for the immune system in the pathophysiology of preeclampsia |
| Q36115311 | A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model |
| Q38246351 | A potential pathophysiological role for galectins and the renin-angiotensin system in preeclampsia |
| Q53700889 | AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. |
| Q35994304 | Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats |
| Q38082526 | Adaptive immune responses during pregnancy |
| Q37507162 | Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy |
| Q36355165 | Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia |
| Q41091522 | Altered Maternal Plasma Glycogen Phosphorylase Isoenzyme BB as a Biomarker for Preeclampsia and Small for Gestational Age. |
| Q36339336 | An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia |
| Q37353499 | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q33789436 | B cells: the old new players in reproductive immunology |
| Q36339273 | Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats |
| Q34508485 | CD4(+) T Cells Play a Critical Role in Mediating Hypertension in Response to Placental Ischemia |
| Q35153877 | CD4+ T cells are important mediators of oxidative stress that cause hypertension in response to placental ischemia. |
| Q38817283 | Comparison of arterial stiffness in preeclamptic and normotensive pregnant women from a semi-rural region of South Africa |
| Q26852668 | Elucidating immune mechanisms causing hypertension during pregnancy |
| Q37229246 | Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia |
| Q34533218 | Endothelin-1 is not a Mechanism of IL-17 Induced Hypertension during Pregnancy. |
| Q34418125 | Enodthelin 1 is elevated in plasma and explants from patients having uterine leiomyomas |
| Q91942453 | Expression of IL-33 Receptor Is Significantly Up-Regulated in B Cells During Pregnancy and in the Acute Phase of Preterm Birth in Mice |
| Q36351174 | Four Pathways Involving Innate Immunity in the Pathogenesis of Preeclampsia |
| Q36380039 | GPCRs as potential therapeutic targets in preeclampsia. |
| Q36369470 | Glycogen phosphorylase isoenzyme BB plasma concentration is elevated in pregnancy and preterm preeclampsia |
| Q36115279 | Hypertension in response to CD4(+) T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system. |
| Q34025660 | Hypertension, inflammation and T lymphocytes are increased in a rat model of HELLP syndrome |
| Q36997267 | IL-10 supplementation increases Tregs and decreases hypertension in the RUPP rat model of preeclampsia |
| Q36178540 | IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy |
| Q37139722 | Identifying immune mechanisms mediating the hypertension during preeclampsia |
| Q36409599 | Immune Mechanisms Linking Obesity and Preeclampsia |
| Q49600503 | Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities |
| Q36422496 | Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms |
| Q39198610 | Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase |
| Q90106114 | Letter to the Editor: Importance of B cells in response to placental ischemia |
| Q38543831 | Linking the old and new -- do angiotensin II type 1 receptor antibodies provide the missing link in the pathophysiology of preeclampsia? |
| Q89454188 | Lipoxin A4 suppresses angiotensin II type 1 receptor autoantibody in preeclampsia via modulating caspase-1 |
| Q47637232 | Natural killer cells mediate pathophysiology in response to reduced uterine perfusion pressure |
| Q27303128 | Neutrophil Depletion Attenuates Placental Ischemia-Induced Hypertension in the Rat |
| Q90259719 | Placental Origins of Preeclampsia: Potential Therapeutic Targets |
| Q88542480 | Placental ischemia-stimulated T-helper 17 cells induce preeclampsia-associated cytolytic natural killer cells during pregnancy |
| Q88194244 | Postpartum increases in cerebral edema and inflammation in response to placental ischemia during pregnancy |
| Q48523077 | Preeclampsia: From Inflammation to Immunoregulation |
| Q35159241 | Preventing autoimmunity protects against the development of hypertension and renal injury |
| Q38691672 | Proliferation of endogenous regulatory T cells improve the pathophysiology associated with placental ischaemia of pregnancy |
| Q39136791 | Recent Advances in Immunity and Hypertension |
| Q37376964 | Recent advances in the understanding of the pathophysiology of preeclampsia |
| Q35707881 | Receptor-activating autoantibodies and disease: preeclampsia and beyond |
| Q45350029 | Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia |
| Q52715243 | The Role of Interleukin-10 in the Pathophysiology of Preeclampsia. |
| Q36716822 | The Role of PPARs in Placental Immunology: A Systematic Review of the Literature |
| Q33957722 | The immune system in hypertension |
| Q53064232 | The immune system in hypertension. |
| Q38014802 | The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms |
| Q27003301 | The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? |
| Q38076773 | The role of B cells in pregnancy: the good and the bad. |
| Q33834419 | The role of inflammation in the pathology of preeclampsia |
| Q38124456 | Vascular dysfunction in preeclampsia |
| Q34533258 | Vitamin D Supplementation Suppresses Hypoxia-Stimulated Placental Cytokine Secretion, Hypertension and CD4(+) T Cell Stimulation in Response to Placental Ischemia |
| Q36699839 | Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia |
| Q51294484 | Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in preeclampsia including hypertension. |
Search more.